Generated by AI
Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products. The company specializes in medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity, designed to help prevent viruses, allergens, and other airborne particles from contacting nasal tissue. Its proprietary Capture and Contain technology is intended to create a temporary shield in the nose, while its Trap and Target platform supports intranasal delivery of active pharmaceutical ingredients. Polyrizon also develops product candidates aimed at nasal allergy blocking and influenza protection. In addition to preventative intranasal solutions, the company works on improving bioadhesion and retention characteristics for drug delivery applications. Polyrizon Ltd. serves the healthcare and biotechnology markets through research, development, and commercialization of nasal-care technologies.
Website5 HaPnina Street
Ra'anana, 4321545
Israel
The latest articles about PLRZ.
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that its Board of Directors (the “Board”) has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. “Unfortunately, Polyrizon, like many other development-stage biotech companies, continues to experience a signifi
Summary of Jul 7's posts. Generated by AI.
Summary of Feb 2's posts. Generated by AI.
No summary yet.
Summary of Apr 15's posts. Generated by AI.
Investors talking about PLRZ also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.